Глава 7. Атопический дерматит

Flohr C. Recent perspectives on the global epidemiology of childhood eczema // Allergol. Immunopathol. (Madr.). 2011. Vol. 39. P. 174–182.

Flohr C., England K., Radulovic S. et al. Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age // Br. J. Dermatol. 2010. Vol. 163. N. 6. P. 1333–1336.

Flohr C., Mann J. New insights into the epidemiology of childhood atopic dermatitis // Allergy. 2014. Vol. 69. P. 3–16.

Fortugno P., Bresciani A., Paolini C. Proteolytic activation cascade of the Netherton syndrome — defective protein, LEKTI, in the epidermis: Implications for skin homeostasis // J. Invest. Dermatol. 2011. Vol. 131. P. 2223–2232.

Gelmetti C., Frasin A.L. Infantile seborreic dermatitis: a disappearing disease // Eur. J. Pediatr. Dermatol. 2008. Vol. 18. P. 155–156.

Gelmetti C.M., Grimalt R. Infantile seborrhoeic dermatitis // Harper’s Textbook of Pediatric Dermatology. In 2 vols / Eds A.D. Irvine, P.H. Hoeger, A.C. Yan. 3rd ed. Oxford: Wiley, 2011. Vol. 1. Chap. 35.

Gonzalez T., Biagini Myers J.M., Herr A.B. et al. Staphylococcal biofilms in atopic dermatitis // Curr. Allergy Asthma Rep. 2017. Vol. 17. N. 12. P. 81. DOI: https://doi.org/10.1007/s11882-017-0750-x.

Granato L. Modulator from fractions of vegetable unsaponifiables // Personal Care. 2012. Vol. 9. Р. 69–72.

Hadson T.J. Skin barrier function and allergic risk // Nat. Genet. 2006. Vol. 38. N. 4. P. 399–400.

Harding C.R., Aho S., Bosko C.A. Filaggrin — revisited // Int. J. Cosmet. Sci. 2013. Vol. 35. N. 5. P. 412–423.

Hay R.J., Johns N.E., Williams H.C. et al. The global burden of skin disease in 2010: An analysis of the prevalence and impact of skin conditions // J. Invest. Dermatol. 2014. Vol. 134. N. 6. P. 1527–1534.

Hill D.A., Spergel J.M. The atopic march: Critical evidence and clinical relevance // Ann. Allergy Asthma Immunol. 2018. Vol. 120. N. 2. P. 131–137.

Holm J.G., Agner T., Clausen M.L., Thomsen S.F. Quality of life and disease severity in patients with atopic dermatitis // J. Eur. Acad. Dermatol. Venereol. 2016. Vol. 30. P. 1760–1767.

Hoste E., Kemperman P., Devos M. et al. Caspase-14 is required for filaggrin degradation to natural moisturizing factors in the skin // J. Invest. Dermatol. 2011. Vol. 131. P. 2233–2241.

Howell M.D., Kim B.E., Gao P. et al. Cytokine modulation of atopic dermatitis filaggrin skin expression // J. Allergy Clin. Immunol. 2009. Vol. 124. P. R7–R12.

Hywel C. Williams Epidemiology of human atopic dermatitis — seven areas of notable progress and seven areas of notable ignorance // Vet. Dermatol. 2013. Vol. 24. P. 3–9.

Irvine A.D., McLean W.H., Leung D.Y. Filaggrin mutations associated with skin and allergic diseases // N. Engl. J. Med. 2011. Vol. 365. P. 1315–1327.

Jesenak M., Plamenova I., Plank L., Banovcin P. Wiskott-Aldrich syndrome caused by a new mutation associated with multifocal dermal juvenile xanthogranulomas // Pediatr. Dermatol. 2013. Vol. 30. N. 5. P. 91–94.

Jonca N., Leclerc E.A., Caubet C. et al. Corneodesmosomes and corneodesmosin: from the stratum corneum cohesion to the pathophysiology of genodermatoses // Eur. J. Dermatol. 2011. Vol. 21. Suppl. 2. P. 35–42.

Jung A.G., Mathony U.A., Behre B. et al. Acrodermatitis enteropathica: An uncommon differential diagnosis in childhood — first description of a new sequence variant // J. Dtsch. Dermatol. Ges. 2011. Vol. 9. N. 12. P. 999–1002.

Kabashima-Kubo R., Nakamura M., Sakabe J. et al. A group of atopic dermatitis without IgE elevation or barrier impairment shows a high Th1 frequency: possible immunological state of the intrinsic type // J. Dermatol. Sci. 2012. Vol. 67. N. 1. P. 37–43.

Kamata Y., Taniguchi A., Yamamoto M. et al. Neutral cysteine protease bleomycin hydrolase is essential for the breakdown of deiminated filaggrin into amino acids // J. Biol. Chem. 2009. Vol. 284. P. 12 829–12 836.

Kantor R., Silverberg J.I. Environmental risk factors and their role in the management of atopic dermatitis // Expert Rev. Clin. Immunol. 2017. Vol. 13. P. 15–26.

Karadag A.S., Bilgili S.G., Calka O. Acrodermatitis enteropathica in three siblings // Indian J. Dermatol. Venereol. Leprol. 2013. Vol. 79. N. 2. P. 268–269.

Kawasaki H., Nagao K., Kubo A. et al. Altered stratum corneum barrier and enhanced percutaneous immune responses in filaggrin-null mice // J. Allergy Clin. Immunol. 2012. Vol. 129. N. 6. P. 1538–1546.

Kawasaki Y., Toyoda H., Otsuki S. et al. A novel Wiskott-Aldrich syndrome protein mutation in an infant with thrombotic thrombocytopenic purpura // Eur. J. Haematol. 2013. Vol. 90. N. 2. P. 164–168.

Kim J.P., Chao L.X., Simpson E.L., Silverberg J.I. Persistence of atopic dermatitis (AD): A systematic review and meta-analysis // J. Am. Acad. Dermatol. 2016. Vol. 75. P. 681–687.

Kottke M.D., Delva E., Kowalczyk A.P. The desmosome: cell science lessons from human diseases // J. Cell Sci. 2006. Vol. 119. Pt 5. P. 797–806.

Larralde M. Langerhans cell histiocytosis in children under one year // Arch. Argent. Pediatr. 2008. Vol. 106. N. 3. P. 269–272.

Leung M.B.D. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation // Imunnol. Rev. 2011. Vol. 242. N. 1. P. 233–246.

Levin J., Friedlander S.F., Del Rosso J.Q. Atopic dermatitis and the stratum corneum — part 1: the role of filaggrin in the stratum corneum barrier and atopic skin // J. Clin. Aesthet. Dermatol. 2013. Vol. 6. N. 10. P. 16–22.

Levin J., Friedlander S.F., Del Rosso J.Q. Atopic dermatitis and the stratum corneum — part 2: other structural and functional characteristics of the stratum corneum barrier in atopic skin // J. Clin. Aesthet. Dermatol. 2013. Vol. 6. N. 11. P. 49–54.

Lyons J.J., Milner J.D., Stone K.D. Atopic dermatitis in children: clinical features, pathophysiology, and treatment // Immunol. Allergy Clin. North Am. 2015. Vol. 35. N 1. P. 161–183.

McGrath J.A. Filaggrin and skin barrier defects // Australas. J. Dermatol. 2008. Vol. 49. P. 67–74.

Minkov M. Multisystem Langerhans cell histiocytosis in children // Paediatr. Drugs. 2011. Vol. 13. N. 2. P. 75–86.

Mohan G.C., Lio P.A. Comparison of dermatology and allergy guidelines for atopic dermatitis management // JAMA Dermatol. 2015. Vol. 151. P. 1009–1013.

Mori T., Ishida K., Mukumoto S. et al. Comparison of skin barrier function and sensory nerve electric current perception threshold between IgE-high extrinsic and IgE-normal intrinsic types of atopic dermatitis // Br. J. Dermatol. 2010. Vol. 162. N. 1. P. 83–90.

Morizane S., Yamasaki K., Kajita A. et al. TH2 cytokines increase kallikrein 7 expression and function in patients with atopic dermatitis // J. Allergy Clin. Immunol. 2012. Vol. 130. N. 1. P. 259–261.

Nidner R. Therapy with systemic glucocorticoids // Hautartzt. 2001. Vol. 52. P. 1062–1071.

Novak N., Simon D. Atopic dermatitis — from new pathophysiologic insights to individualized therapy // Allergy. 2011. Vol. 66. P. 830–839.

Nowicka D., Grywalska E. The role of immune defects and colonization of Staphylococcus aureus in the pathogenesis of atopic dermatitis // Anal. Cell. Pathol. (Amst.). 2018. Vol. 2018. Article ID 1956403.

Oji V., Eckl K.M., Aufenvenne K. et al. Loss of corneodesmosin leads to severe skin barrier defect, pruritus, and atopy: unraveling the peeling skin disease // Am. J. Hum. Genet. 2010. Vol. 87. N. 2. P. 274–281.

Otsuka A., Nomura T., Rerknimitr P. et al. The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis // Immunol. Rev. 2017. Vol. 278. N. 1. P. 246–262.

Paller A.S., Siegfried E.C., Thaçi D. et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial // J. Am. Acad. Dermatol. 2020. Vol. 83. N. 5. P. 1282–1293.

Paller A.S., Tom W.L., Lebwohl M.G. et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults // J. Am. Acad. Dermatol. 2016. Vol. 75. N. 3. P. 494–503.

Parker J.J., Sugarman J.L., Silverberg N.B. et al. Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children // Pediatr. Dermatol. 2021. Vol. 38. P. 1500–1505. DOI: https://doi.org/10.1111/pde.14820.

Peng W., Novak N. Pathogenesis of atopic dermatitis // Clin. Exp. Allergy. 2015. Vol. 45. N. 3. P. 566–574.

Puar N., Chovatiya R., Paller A.S. New treatments in atopic dermatitis // Ann. Allergy Asthma Immunol. 2021. Vol. 126. N 1. P. 21–31.

Rerknimitr P., Otsuka A., Nakashima C., Kabashima K. The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus // Inflamm. Regen. 2017. Vol. 37. N. 1. P. 14.

Ring J., Alomar A., Bieber T. et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I // J. Eur. Acad. Dermatol. Venereol. 2012. Vol. 26. N. 8. P. 1045–1060.

Ring J., Alomar A., Bieber T. et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part II // J. Eur. Acad. Dermatol. Venereol. 2012. Vol. 26. N. 9. P. 1176–1193.

Samuelov L., Sarig O., Harmon R.M. et al. Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting // Nat. Genet. 2013. Vol. 45. N. 10. P. 1244–1248.

Scharschmidt T.C., Man M.-Q., Hatano Y. et al. Filaggrin deficiency confers a paracellular barrier abnormality that reduces inflammatory thresholds to irritants and haptens // J. Allergy Clin. Immunol. 2009. Vol. 124. N. 3. P. 496–506.

Scheerer C., Eyerich K. Pathogenese des atopischen Ekzems // Hautarzt. 2018. Vol. 69. N. 3. P. 191–196.

Seegraber M., Srour J., Walter A. et al. Dupilumab for treatment of atopic dermatitis // Expert Rev. Clin. Pharmacol. 2018. Vol. 11. N. 5. P. 467–474.